Loading...

Evotec SE

0IRF.ILIOB
Healthcare
Drug Manufacturers - Specialty & Generic
£6.68
£-0.26(-3.73%)

Evotec SE (0IRF.IL) Financial Performance & Income Statement Overview

Explore the financials of Evotec SE (0IRF.IL), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
1.99%
1.99%
Operating Income Growth
-200.00%
200.002%
Net Income Growth
-133.67%
133.67%
Operating Cash Flow Growth
-50.00%
50.00%
Operating Margin
-18.31%
18.31%
Gross Margin
13.62%
13.62%
Net Profit Margin
-26.26%
26.26%
ROE
-21.53%
21.53%
ROIC
-9.09%
9.09%

Evotec SE (0IRF.IL) Income Statement & Financial Overview

Explore comprehensive income reports for Evotec SE 0IRF.IL, broken down by year and quarter.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$221.23M$184.89M$182.12M$208.73M
Cost of Revenue$175.13M$166.61M$166.38M$173.97M
Gross Profit$46.10M$18.28M$15.74M$34.76M
Gross Profit Ratio$0.21$0.10$0.09$0.17
R&D Expenses$9.73M$11.87M$13.01M$16.24M
SG&A Expenses$49.90M$46.39M$45.97M$45.94M
Operating Expenses$39.31M$44.78M$58.98M$62.18M
Total Costs & Expenses$214.44M$211.38M$225.36M$236.15M
Interest Income-$367000.00$917000.00$467000.00$1.42M
Interest Expense$4.42M$1.87M$2.74M$2.67M
Depreciation & Amortization$0.00$0.00$1.45M$17.77M
EBITDA-$11.45M-$45.008M-$103.17M-$15.95M
EBITDA Ratio-$0.05-$0.24-$0.57-$0.08
Operating Income$6.78M-$26.49M-$104.61M-$27.42M
Operating Income Ratio$0.03-$0.14-$0.57-$0.13
Other Income/Expenses (Net)-$22.65M-$20.38M$151000.00$638000.00
Income Before Tax-$15.87M-$46.87M-$104.45M-$25.73M
Income Before Tax Ratio-$0.07-$0.25-$0.57-$0.12
Income Tax Expense$24.97M-$7.24M-$9.52M-$6.11M
Net Income-$40.84M-$39.63M-$94.93M-$20.67M
Net Income Ratio-$0.18-$0.21-$0.52-$0.10
EPS-$0.23-$0.22-$0.54-$0.12
Diluted EPS-$0.23-$0.22-$0.54-$0.12
Weighted Avg Shares Outstanding$177.30M$177.35M$177.30M$177.30M
Weighted Avg Shares Outstanding (Diluted)$177.30M$177.35M$177.30M$177.30M

Over the last four quarters, Evotec SE's revenue moved from $208.73M in Q1 2024 to $221.23M in Q4 2024. Operating income in Q4 2024 was $6.78M, with a strong operating margin of 3%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Evotec SE remained robust at -$11.45M, reflecting operational efficiency. Net income dropped to -$40.84M, with an EPS of -$0.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;